Align Technology ALGN

Healthcare · Medical - Devices · Synthos Deep Dive · 2026-07-03

$157.58

Buy — Tactical

—

The Overview

Align makes Invisalign — the clear plastic braces you wear instead of metal ones — and the iTero 3D mouth scanners dentists use to fit them. It basically invented the category and still dominates it.

The problem is simple: growth has stalled. During the pandemic, everyone stuck at home on video calls wanted straighter teeth, and sales boomed. That wave is over. Sales grew less than 1% last year, and the stock is down about 5% over the past twelve months while the overall market is up more than 20%. The company itself is high quality — it keeps about 68 cents of gross profit per sales dollar and has more cash than debt — but a great company with no growth is only worth so much.

The stock isn't expensive, but it isn't a bargain either. Our verdict is Watch — a good company to keep an eye on, but there's no obvious reason to rush in until growth picks back up or the price falls.

Here's what our three scores mean in everyday terms:

Downside Risk 5/10 (middle). The balance sheet is rock-solid (more cash than debt), but the stock swings hard (it has fallen 75% from a past peak) and demand for dental work drops when people feel poorer.
Growth Quality 5/10 (average). Very profitable, but barely growing right now — most of the earnings growth comes from buying back shares, not selling more product.
Exponential Potential 3/10 (low). The long-run opportunity (billions of people with crooked teeth) is huge, but Align is converting it slowly, and growth is going the wrong direction lately.

The one big worry: the core business has stopped growing. Until Invisalign case volumes re-accelerate, the stock has no engine.

Putting a number on it: our fair-value estimate is $210 against a current price of $157.58 — real upside if our numbers are right.

Target entry zone $142 – $158 accumulate in this band; ideal adds on further weakness toward $142 (~10% below the last price; both moving averages sit overhead — the 200-day at $170), keeping roughly a 25% margin below our $210 base-case fair value

Our summary metrics

Downside Risk (lower = safer)5/10Moderate

Net-cash fortress balance sheet, but beta 1.67, elective-demand cyclicality, and a brutal −75% historical drawdown.

Growth Quality5/10Moderate

Revenue near-flat (+0.9% FY25), ~5% fwd rev CAGR; EPS growth is buyback/margin-led, not volume-led.

Exponential Potential3/10Low

Mature, decelerated off the 2021 peak; huge TAM but slow penetration — a compounder, not an exponential.

Fair value$210 $155–$252

What does “fair value” mean?

Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.

The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)

Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.

Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.

WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.

HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.

AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

Exponential Potential

Exponential Potential3/10Low

Mature, decelerated off the 2021 peak; huge TAM but slow penetration — a compounder, not an exponential.

What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.

Deeper analysis

Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.

Check our number Market-implied growth ≈ -9%/yr This isn’t how we calculate fair value — it’s public math you can verify yourself. To justify today’s $158, earnings would have to compound roughly -9% a year for 10 years (9% discount rate). Analysts forecast ~12%/yr, so the market is pricing in LESS than what the Street expects.

Reference table

Street consensus	$204 (high $235 / low $185; 24 Buy · 7 Hold · 2 Sell) — context, not our anchor
Valuation	33× trailing GAAP EPS · 16× FY26E · 15× FY27E · 12× FY29E (non-GAAP) · EV/S 3.0× · EV/EBITDA 13.5×
Technicals	Neutral-to-up — $184.52, above 50/200-DMA, RSI 56, but −5% 12-mo while SPY +21% (a laggard)
Conviction	Low — zero Synthos KB claims; call rests entirely on fundamentals + quant
Position sizing	Small satellite only, ~1–2% if bought at all; wait for a growth re-acceleration or a cheaper entry

What the experts actually said

No independent expert claims in the Synthos knowledge base yet for ALGN — this dive is fundamentals- and technicals-driven, not panel-driven.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 37.

MACD 12 / 26 / 9 · trend & momentum

The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago

Solid = ALGN · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$157.58

Market cap$11B

P/E trailing27×

P/E FY26E / FY27E14× / 13×

EV / Sales2.5×

EV / EBITDA13.1×

Gross margin66.5%

Net margin10.0%

Dividend yield0.00%

Beta1.653

52-wk range$125 – $198

RSI(14)28

50 / 200-DMA$173 / $170

12-mo return+11% (SPY +19%)

Street target$205 ($188–$235)

Analyst grades24 Buy · 7 Hold · 2 Sell

FMP ratingB+

Next earnings2026-07-29 (Q2'26 earnings; Street EPS est $2.56, rev ~$1.06B)

1. What it is

Align Technology (NASDAQ: ALGN) is a ~$13B medical-device company headquartered in Tempe, Arizona, founded in 1997. It designs, makes, and sells two things that work together: Invisalign clear dental aligners and iTero digital intraoral scanners (plus exocad CAD/CAM software). CEO Joseph Hogan; ~21,200 employees; fiscal year ends December 31.

The business is a genuine razor-and-blade flywheel: iTero scanners get placed in dental and orthodontic practices, and those scanners drive Invisalign case starts. Two reported segments:

Revenue mix (FY2025, from filings):

By segment: Clear Aligner $3.25B (80%) · Scanners & Services $0.79B (20%). Clear Aligner is the engine; Scanners is the on-ramp.
By geography (FMP tags): United States $1.66B (41%) · Switzerland (the international/EMEA billing hub) $0.92B · Other International $1.45B. Roughly ~59% of revenue is non-US, so FX and international elective-demand cycles matter a lot (management called out a ~$45M YoY FX tailwind in Q1'26).

The strategic story management is selling: the Align Digital Platform, scaling the iTero Lumina scanner ecosystem, international expansion with localized strategies, and a differentiated portfolio for teens and growing kids (the largest untapped orthodontic pool).

2. The expert thesis — why the panel is bullish (traceable)

There is no expert coverage for ALGN in the Synthos knowledge base. total_claims = 0; there are zero net-bullish (or bearish) voices distilled for this name. Unlike a conviction-track flagship, nothing in this note rests on a cited expert claim_id, because none exist.

That is stated plainly and by design: the House Standard forbids manufacturing conviction. This verdict is therefore entirely fundamentals- and quant-driven — built from the FMP financials, analyst estimates, the SEC 8-K guidance, and the valuation/technical work below. Read the scores and the Bull/Base/Bear cases as a quantitative read, not as an endorsement by any tracked expert.

For external context only (not Synthos conviction): the sell-side is constructive — 24 Buy / 7 Hold / 2 Sell, consensus "Buy," FMP letter rating A−. That is Wall Street's book, shown as context, not our anchor.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score	0–10	The read
Downside Risk (lower = safer)	5 · Moderate	Net cash (net-debt/EBITDA −1.0×), 68% gross margin and ~$490M FCF make it sturdy — but beta 1.67, elective-demand cyclicality, ~59% non-US/FX exposure, and a historical −75% max drawdown cut the other way.
Growth Quality	5 · Average	Revenue near-flat (+0.9% FY25), ~5% forward rev CAGR; non-GAAP EPS growth (~11–12%) is buyback- and margin-led, not volume-led. ROE ~11%, ROIC ~10% — good, not elite.
Exponential Potential	3 · Low	Mature and decelerated off the 2021 peak (revenue is still below its 2021 $3.95B level). Huge TAM but slow penetration; $13B cap has room, but no acceleration to fuel it.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them. (EPS below are non-GAAP, the basis analyst estimates are quoted on — GAAP EPS is materially lower; see §5–6.)

Case	Key assumptions	Fair value
Bull	International + teen/kid volume re-accelerates; iTero Lumina drives case starts; margins recover toward 22% non-GAAP op. FY27E non-GAAP EPS beats to ~$12.6 (vs $12.36 cons); multiple re-rates to ~20×.	~$252 (+37%)
Base (our anchor)	Estimates roughly hit — FY27E non-GAAP EPS $12.36; a low-single-digit grower with a fortress balance sheet earns a ~17× multiple.	~$210 (+14%)
Bear	Volume stays flat, FX turns to a headwind, price competition from generics/DTC compresses ASPs. FY27E non-GAAP EPS misses to ~$12.0; multiple de-rates to ~13×.	~$155 (−16%)

Synthos fair value = the base case, ~$210 (+14%), with the full $155–$252 span as the honest range. Our base sits essentially in line with the Street's $204 consensus (this is a well-covered, efficiently-priced large-cap; we have no differentiated edge to justify a big gap). This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ALGN is neither an exponential nor, right now, even a fast compounder — it is a stalled category leader:

Forward growth: revenue CAGR FY25→FY29E ~4.9% ($4.03B → $4.89B); non-GAAP EPS CAGR FY26→FY29E ~11.5% ($11.37 → $15.77), and the gap between the two tells the story — EPS grows ~2× faster than revenue because of buybacks and margin, not units.
Acceleration (the 2nd derivative) is muted and only mildly positive off a low base: revenue growth +0.9% (FY25) → +3.7% (FY26E) → +4.3% (FY27E) → +5.5% (FY28E). That is a gentle recovery from a stall, not an inflection. Revenue is still below the FY2021 pandemic peak of $3.95B four years later.
Room to run: the orthodontic TAM is genuinely enormous — hundreds of millions of malocclusion cases globally, only a low-single-digit share treated with clear aligners. The runway exists; the conversion rate is the problem. A $13B cap has room to 3–4× if penetration re-accelerates — but nothing in the numbers says it is.
Reinvestment runway: modest, disciplined capex (~$102M FY25, only ~0.8% of operating cash flow) and heavy buybacks. This is a return-of-capital story now, not a reinvest-for-hypergrowth story.

Exponential Potential: Low (3/10). Own ALGN for quality and a possible re-rating on a volume recovery — not for exponential growth. Per our flagship philosophy we pick forward next-exponentials over trailing compounders; ALGN is a trailing compounder that has temporarily stopped compounding.

5. Financials (real numbers — FMP annual/quarterly)

Revenue: FY25 $4.035B, +0.9% (FY24 $3.999B, +3.5% on FY23 $3.863B). Essentially flat; the multi-year story is a plateau after the 2020–21 boom.
Quarterly trajectory: Q1'25 $979M → Q2 $1,012M → Q3 $996M → Q4 $1,048M → Q1'26 $1,040M (+6.2% YoY, helped by ~$45M FX). Volume growth is real but low-single-digit; Clear Aligner cases +6.7% YoY in Q1'26.
Margins: gross 68.3% FY25 (Q1'26 GAAP gross margin 70.8%, non-GAAP 71.8%); GAAP operating margin ~15% FY25 (Q1'26 13.6% GAAP / 21.5% non-GAAP). The GAAP-vs-non-GAAP gap is large — stock comp (~$186M/yr) and amortization drive most of it. Net margin 10.2% TTM.
Earnings: GAAP net income $410M FY25, GAAP EPS $5.66 (down from $5.63 FY24 — flat). TTM GAAP EPS ~$6.02. Non-GAAP diluted EPS ran ~$2.13→$3.29 per quarter in FY25; analyst FY-EPS estimates ($11.37 FY26E etc.) are on the non-GAAP basis — do not compare them to the 33× trailing GAAP multiple.
Cash flow: operating CF $593M, capex only −$102M, FCF ~$491M FY25 (FCF yield ~5.2% on EV). Clean, high-conversion cash generation.
Balance sheet: net cash — cash & ST investments $1.09B vs total debt $114M (all leases), net debt −$965M, net-debt/EBITDA −1.0×. Fortress. Buybacks: ~$466M repurchased in FY25, with $800M remaining on the $1.0B program and another $200M tranche underway.

6. Valuation — priced in or room?

Two very different pictures depending on the earnings basis:

On GAAP: 33× trailing EPS ($184.52 / $5.66 FY25) — looks rich, because GAAP earnings are depressed by heavy stock comp and amortization.
On the non-GAAP basis analysts actually use: forward P/E is 16.2× (FY26E) → 14.9× (FY27E) → 13.6× (FY28E) → 11.7× (FY29E). That is a reasonable, arguably slightly cheap multiple for a 68%-gross-margin, net-cash, FCF-generative category leader.
EV-based (basis-agnostic): EV/EBITDA 13.5×, EV/Sales 3.0×, P/FCF ~19× — all mid-range for a quality medtech name, neither stretched nor a screaming bargain.

The honest read: ALGN is fairly valued. The multiple already reflects both the quality (net cash, margins, FCF) and the disappointment (flat revenue). For the stock to work you need either (a) a volume re-acceleration that lifts estimates, or (b) a re-rating as the market gains confidence in the recovery. Neither is in hand today. Street targets (context): consensus $204, high $235, low $185 — our $210 base is right on top of consensus because we see no differentiated edge on an efficiently-priced large-cap. Not a value trap, not a bargain — a fairly-priced quality name in a growth pause.

7. Technicals (from the tech block)

Trend: mildly up. $184.52 sits above the 50-DMA ($172) and 200-DMA ($162), and the 50 is above the 200 (constructive posture). MACD +2.07 (mildly positive).
Location: −10.9% off the 52-week high ($207) and +47.8% off the 52-week low ($125) — mid-range, not extended. Note the sobering long-run stat: max drawdown from peak −74.7% (this stock can halve and halve again — it did after 2021).
Momentum: RSI(14) 55.7 — neutral, neither overbought nor oversold. No stretched-entry signal, no capitulation signal.
Relative strength (the tell): ALGN is −5.0% over 12 months while SPY is +20.6% and QQQ +30.3% — a clear laggard. Shorter-term it has firmed: +6.8% 3-mo, +16.7% 6-mo, roughly matching or slightly trailing SPY. The price action says "bottoming and stabilizing," not "leadership."
Read: technicals are neutral-to-constructive but unconfirmed — above the moving averages and off the lows, but a year of underperformance means the market is still waiting for proof of a growth turn. No urgency; a pullback toward the rising 200-DMA (~$162) would be a lower-risk entry.

8. Moat & competitive position

Align's moat is real but narrowing: (1) the Invisalign brand is synonymous with clear aligners and carries pricing power with orthodontists and patients; (2) a razor/razor-blade flywheel — iTero scanner placements drive Invisalign case starts and switching costs into the Align Digital Platform; (3) data and clinical scale — decades of treatment outcomes feed software (ClinCheck, outcome simulators). Offsetting that: original composition-of-matter patents have largely expired, direct-to-consumer and low-cost generic aligners compete on price, and volume growth has stalled, which is what a moat under pressure looks like.

Peer set (FMP tags — a medtech grab-bag, market cap): BioMarin $11.4B, Penumbra $12.5B, Revvity $12.7B, Exelixis $14.0B, Globus Medical $10.8B, Bio-Rad $8.0B, Qiagen $8.3B, Ensign Group $9.8B, Hims & Hers $8.2B. None is a true clear-aligner comp — ALGN's real competition is private/DTC aligner makers and legacy metal-bracket orthodontics, which the peer list doesn't capture. Read the peer set as "similar-size healthcare," not as direct rivals.

9. Management, capital allocation & guidance

Capital allocation: disciplined and shareholder-friendly. Light capex (~$102M/yr), no dividend, and aggressive buybacks — ~$466M repurchased in FY25, ~1.4M shares at avg $143.85 completing a $200M tranche, with $800M remaining on the $1.0B authorization and a fresh $200M six-month tranche starting ~May 2026. With net cash and ~$491M FCF, buybacks are well-funded and are the primary EPS growth lever right now.
Insider activity: the sampled Form 4s (filed 2026-05-22) are routine director equity awards and RSU vesting (grants/M-Exempt conversions), not open-market discretionary selling. No alarming signal in the window.
Management's own guidance (half-weighted — their book): the SEC 8-K (Q1'26 earnings release, filed 2026-04-29) reaffirmed fiscal-2026 guidance and announced an additional $200M buyback. Management reported "another better-than-expected quarter" with Q1'26 revenue $1,040M (+6.2% YoY), record Clear Aligner shipments of 685.7K (+6.7% YoY) driven by double-digit international growth and North America stability, and non-GAAP operating margin 21.5%. CEO Joe Hogan framed 2026 priorities as "maintaining discipline as we strategically invest in innovation and growth" — the Align Digital Platform, iTero Lumina scaling, international expansion, and the teen/kid portfolio. Note: the press-release text truncates just as the detailed FY26 revenue/margin outlook table begins, so specific FY26 revenue-growth and margin targets are not fully captured here — treat "reaffirmed guidance + better-than-expected Q1" as the honest takeaway, and confirm the exact numbers at the Q2 print. Management's words are self-interested and half-weighted by design.

10. Catalysts & what to watch

Next earnings: 2026-07-29 (Q2'26; Street EPS $2.56 non-GAAP, revenue ~$1.06B). The key line: Clear Aligner case volume growth (is the mid-single-digit re-acceleration holding?) and North America trend.
iTero Lumina adoption: scanner placements are the leading indicator of future Invisalign case starts — watch the Systems & Services growth rate ex-FX.
International + teen/kid volume: the double-digit international growth and teen/kid patient adds are the clearest path to re-acceleration.
FX: ~59% of revenue is non-US; the ~$45M YoY tailwind in Q1'26 can reverse — separate real volume from currency.
Buyback pace / ASPs: continued repurchases support EPS; watch for any ASP erosion from DTC/generic price competition.

Thesis tripwires (what would change the call): two consecutive quarters of Clear Aligner volume deceleration back toward flat; a guidance cut; non-GAAP operating margin slipping below ~20%; or ASP declines signaling real price competition. Conversely, two quarters of high-single-digit volume growth would upgrade this from Watch toward Buy.

11. Key risks

Growth stall (structural): revenue is roughly flat and still below its 2021 peak; the entire investment case depends on volume re-accelerating, which is not yet proven.
Elective-demand cyclicality: orthodontics is discretionary and consumer-financed; a consumer slowdown hits case starts directly (beta 1.67 reflects this).
Competition / ASP pressure: expired core patents, DTC aligners, and low-cost generics can erode both share and pricing over time.
FX & international concentration: ~59% non-US revenue makes reported growth and margins sensitive to the dollar.
Valuation basis confusion: the "cheap" 16× forward multiple is on non-GAAP EPS; GAAP earnings are ~2× lower. Stock-based comp (~4.4% of revenue) is a real cost — don't over-credit the non-GAAP number.
No expert corroboration: with zero Synthos KB claims, there is no independent conviction layer to catch what the quant/fundamental read might miss.

12. Verdict, position sizing & monitoring

Watch. Align is a genuinely high-quality franchise — category-defining brand, 68% gross margin, net-cash balance sheet, ~$491M FCF, disciplined buybacks — trading at a fair (~16× forward non-GAAP) multiple. But the growth engine has stalled: revenue is up less than 1%, the stock has lagged the market by ~25 points over the past year, and there is no expert conviction in the Synthos KB to lean on. A good company at a fair price with no near-term catalyst is a Watch, not a Buy — you are not paid to own a growth pause.

Sizing: if bought at all, a small satellite (~1–2%). Prefer to wait for either (a) two quarters of proven volume re-acceleration, or (b) a pullback toward the rising 200-DMA (~$162) for a better margin of safety.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. Upgrade path to Buy — Tactical is explicit: sustained high-single-digit Clear Aligner volume growth. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $184.52.
Single biggest risk: the structural growth stall — until Invisalign volumes re-accelerate, the stock has no engine.

Provenance & disclosures

Traceability: 0 KB claims, breadth 0 — ALGN has no expert coverage in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no expert claim_id is cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation), and none is claimed here.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · SEC 8-K guidance filed 2026-04-29. Forward figures are analyst consensus (FMP) on a non-GAAP basis, labeled as estimates.
Management caveat: the FY26 guidance summarized in §9 is management's own book, half-weighted by design, and the press-release text truncated before the full outlook table — confirm exact targets at the Q2 print.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").